ClearPoint Neuro Inc. (CLPT)
NASDAQ (CM) NASDAQ (CM) Primary 
ClearPoint Neuro (CLPT) Surges 26.0%: Is This an Indication of Further Gains?
ClearPoint Neuro (CLPT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Compared to Estimates, ClearPoint Neuro (CLPT) Q1 Earnings: A Look at Key Metrics
Although the revenue and EPS for ClearPoint Neuro (CLPT) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
ClearPoint Neuro, Inc. (CLPT) Reports Q1 Loss, Lags Revenue Estimates
ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.22 per share a year ago.
ClearPoint Neuro Q1 Earnings Call Highlights
ClearPoint Neuro NASDAQ: CLPT reported record first-quarter 2026 revenue and reaffirmed its full-year outlook, as management highlighted growth in its legacy neurosurgical device business and early contributions from the recently acquired IRRAflow product line.
ClearPoint Neuro: Temporary Headwinds Don't Change The Long-Term Outlook
ClearPoint's stock has come under significant pressure in recent months following weaker 2026 revenue guidance and further regulatory uncertainty. Despite near-term headwinds, a step change in revenue remains likely as partner therapies are commercialized over the next few years. Independent of this, ClearPoint's forward revenue multiple looks increasingly reasonable given the company's strong competitive positioning and solid growth.
ClearPoint Neuro, Inc. (CLPT) Q4 2025 Earnings Call Transcript
ClearPoint Neuro, Inc. (CLPT) Q4 2025 Earnings Call Transcript
ClearPoint Neuro, Inc. (CLPT) Reports Q4 Loss, Tops Revenue Estimates
ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.2 per share a year ago.
ClearPoint Neuro (CLPT) Moves 8.1% Higher: Will This Strength Last?
ClearPoint Neuro (CLPT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
CLPT Gets EU MDR Certification for ClearPoint Navigation Software
ClearPoint secures EU MDR certification for ClearPoint Navigation Software 3.0.2, expanding precision-guided surgery access across MRI suites and operating rooms.
ClearPoint Neuro: From Validation To Scale
ClearPoint Neuro is positioned for robust growth in 2026, driven by IRRAS, the PRISM 1.5T system clearance, and the company's new CRO facility. While the immediate future of uniQure's AMT-130 remains unknown, ClearPoint has a large number of drug delivery partners that continue to generate strong data. CLPT's valuation is modest given the company's solid competitive positioning and the step change in revenue that will occur when programs in areas like Parkinson's and epilepsy are commercialized.
ClearPoint Neuro, Inc. (CLPT) Q3 2025 Earnings Call Transcript
ClearPoint Neuro, Inc. ( CLPT ) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants Joseph Burnett - President, CEO & Director Danilo D'Alessandro - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets, LLC, Research Division Presentation Operator [Audio Gap] comments made on this call may include statements that are forward-looking within the meaning of securities laws. These forward-looking statements may include, without limitation, statements related to anticipated industry trends, the company's plans, prospects and strategies, both preliminary and projected, the size of total addressable markets or the market opportunity for the company's products and services, the company's expectation for future development, regulatory approval, timing, commercialization and the market for cell and gene therapies and the anticipated adoption of the company's products and services for use in the delivery of gene and cell therapies, and management's expectations, beliefs, estimates or projections regarding future revenue and results of operations.
ClearPoint Neuro: CRO Facility Should Reaccelerate Growth
ClearPoint's third quarter results were weak, which was at least partly due to resource constraints while its new CRO facility was being opened. The near-term outlook for ClearPoint's biopharma business is also now clouded by FDA uncertainty around uniQure's AMT-130. The new CRO facility, PRISM 1.5T clearance, and IRRAS acquisition set ClearPoint up for much stronger growth going forward.
